Comprehensive efficacy of ipragliflozin on various conditioned type 2 diabetes compared with dipeptidyl peptidase-4 inhibitors and with both agents, based on a real-world multicenter trial
Sign Up to like & getrecommendations! Published in 2021 at "Diabetology International"
DOI: 10.1007/s13340-021-00492-8
Abstract: The effects of ipragliflozin, the first sodium-glucose co-transporter 2 inhibitors (SGLT2i) launched in Japan in 2014, and with dipeptidyl peptidase-4 inhibitors (DPP-4i) on glycemic control and metabolic changes were investigated comprehensively on various conditioned type… read more here.
Keywords: peptidase inhibitors; real world; various conditioned; world ... See more keywords